[Lecanemab in Alzheimer’s Disease]

Groppo J, Garcia Martí S, Alfie V, Perelli L, Navarro E, Pichón-Riviere A, Ciapponi A, Augustovski F, Alcaraz A, Bardach A
Record ID 32018004969
Original Title: Lecanemab en enfermedad de Alzheimer
Authors' recommendations: "High-quality evidence shows that lecanemab in patients with early Alzheimer disease (AD) yields a marginal net benefit, since it decreases the quantity of brain beta-amyloid, although this does not translate into clinically significant differences in the Clinical Dementia Rating. Lecanemab use is associated with a 22% risk of presenting edema or intracerebral hemorrhage. The clinical practice guidelines consulted do not mention lecanemab use for patients with Alzheimer’s disease. Regarding the health policies reviewed, most of the Latin American and high-income countries health funders consulted do not mention the use of lecanemab for AD. In Argentina lecanemab is not included in the Mandatory Medical Plan and is not reimbursed by the Unique Reimbursement System. The cost-effectiveness assessments surveyed suggest that lecanemab is not a cost-effective treatment".
Project Status: Completed
Year Published: 2023
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Alzheimer Disease
  • Dementia
  • Drug Therapy
  • Antibodies, Monoclonal, Humanized
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: <p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.